- Home
- PNC vs REGN Comparison
PNC vs REGN Comparison
Compare PNC & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNC
- REGN
- Stock Information
- Founded
- PNC 1852
- REGN 1988
- Country
- PNC United States
- REGN United States
- Employees
- PNC N/A
- REGN N/A
- Industry
- PNC Major Banks
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- PNC Finance
- REGN Health Care
- Exchange
- PNC Nasdaq
- REGN Nasdaq
- Market Cap
- PNC 70.8B
- REGN 63.4B
- IPO Year
- PNC N/A
- REGN 1991
- Fundamental
- Price
- PNC $152.33
- REGN $563.16
- Analyst Decision
- PNC Buy
- REGN Buy
- Analyst Count
- PNC 18
- REGN 23
- Target Price
- PNC $200.17
- REGN $971.57
- AVG Volume (30 Days)
- PNC 3.5M
- REGN 1.1M
- Earning Date
- PNC 04-15-2025
- REGN 04-29-2025
- Dividend Yield
- PNC 4.20%
- REGN 0.16%
- EPS Growth
- PNC 19.02
- REGN 10.27
- EPS
- PNC 14.16
- REGN 38.34
- Revenue
- PNC $21,009,000,000.00
- REGN $14,202,000,000.00
- Revenue This Year
- PNC $11.15
- REGN $4.06
- Revenue Next Year
- PNC $5.31
- REGN $6.54
- P/E Ratio
- PNC $10.76
- REGN $14.69
- Revenue Growth
- PNC 3.14
- REGN 8.27
- 52 Week Low
- PNC $145.12
- REGN $525.99
- 52 Week High
- PNC $216.26
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- PNC 35.13
- REGN 37.15
- Support Level
- PNC $149.75
- REGN $544.50
- Resistance Level
- PNC $159.58
- REGN $575.20
- Average True Range (ATR)
- PNC 7.42
- REGN 28.44
- MACD
- PNC -0.41
- REGN -1.59
- Stochastic Oscillator
- PNC 22.32
- REGN 32.25
About PNC PNC Financial Services Group Inc. (The)
PNC Financial Services Group is a diversified financial services company offering retail banking, corporate and institutional banking, asset management, and residential mortgage banking across the United States.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).